2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Bioinformatics, Treatment Considerations, Combination Therapy, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Clinical Practice (Health Services and Quality), Patient Safety, Quality of Care, Diseases, Immunology, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphomas, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

3644 Clinical outcome of novel immunotherapeutic and targeted therapies in patients with HIV-associated lymphoma

Nathalie Lehnen, Marcus Hentrich, MD2, Leonie Neumann3, Marie Jose Kersten, MD4, Igor Aurer, MD5, Jose Tomas Navarro, MD, PhD6, Andrés José María Ferreri, MD7, Kai Hübel, MD8
1 University of Cologne, Cologne, North Rhine-Westphalia, Germany
2 Red Cross Hospital Munich, Munich, Germany
3 University of Cologne, Cologne, North Rhine-Westphalia, Germany
4 Amsterdam University Medical Center, Amsterdam, Netherlands
5 University Hospital Centre, Zagreb, Croatia
6 Institut Catala d'Oncologia, Barcelona, Spain
7 University Vita-Salute San Raffaele, Milan, Italy
8 University of Cologne, Cologne, North Rhine-Westphalia, Germany

Introduction: People living with human immunodeficiency virus (PLWH) are at increased risk of developing Hodgkin (HL) and Non-Hodgkin lymphoma (NHL) with NHL being the third most common cause of cancer-related death among PLWH. However, PLWH have been excluded from most of the practice-changing clinical trials; therefore, only limited data on efficacy and tolerability of modern treatment options such as T-cell-redirecting therapies, antibody-drug conjugates (ADCs) or checkpoint-inhibitors (CPI) in HIV-associated lymphoma are available. It remains unclear whether these therapies can also be used as standard of care in PLWH who have sustained immunological impairment. Therefore, we conducted a comprehensive database analysis to assess the impact of modern treatment options in HIV-associated lymphoma.

Methods The databases Embase and Medline were searched from January 2015 to September 2025 for HIV-associated lymphoma (diffuse large B-cell lymphoma, DLBCL; classical Hodgkin lymphoma, cHL; Burkitt lymphoma, BL; primary effusion lymphoma, PEL and plasmablastic lymphoma, PBL) treated with modern therapies (CAR-T-cells; bispecific antibodies; pembrolizumab or nivolumab (CPI) and polatuzumab vedotin (PV) or brentuximab vedotin (BV)). Of 1,442 screened publications, 41 studies (clinical trials, prospective and retrospective analyses, case series and case reports) qualified for evaluation. The studies were categorized and analyzed separately according to lymphoma histology and treatment regimen. Data on patient demographics, HIV-related characteristics, treatment lines, toxicities and outcomes were evaluated. The analyses focused on overall response rate (ORR) and complete remission (CR) rate, progression-free survival (PFS), overall survival (OS) and treatment-related toxicities. Additionally, the results were put into context with the outcome of HIV-negative pts in clinical trials.

Results 181 PLWH received at least one of the selected immunotherapeutic or targeted therapies. A total of 38 PLWH (36 DLBCL, 1 follicular lymphoma (FL) and 1 mantle cell lymphoma (MCL)) were treated with CAR-T-cells. All but one received axicabtagene ciloleucel, whereas the MCL pt received brexucabtagene autoleucel. Overall, 41% achieved a CR and 23.5% a partial remission (PR). PFS at 3, 6 and 12 months was 53.8, 45.1 and 35.9%, respectively, with a 6-month OS of 62.7%. Cytokine release syndrome (CRS) was documented in 17 pts (only grade (G) 1-2), 8 pts developed immune effector cell associated neurotoxicity syndrome (ICANS) (G2: 3; G3: 3; G4: 2). Glofitamab was used in 4 pts with DLBCL, of whom 2 achieved CR, 1 PR and 1 progressive disease (PD). No data on epcoritamab or odronextamab in HIV-associated lymphoma were identified. There were 2 DLBCL pts who received polatuzumab vedotin in combination with bendamustin/rituximab, resulting in 1 CR and 1 PR. Of 51 PLWH with cHL treated with CPI monotherapy, 66% achieved a CR, 24% a PR, with 12-month PFS of 78.6% and 12-month OS of 87.5%. More than half of PLWH who received CPIs for cHL had received 3 or more prior treatment lines. BV was used in 58 pts with cHL, of whom 14 received BV-monotherapy and 44 pts received BV in combination with doxorubicin, vinblastine, and dacarbazine (BV-AVD). Remarkably, the overall response rate for BV-AVD was 100%, with 37 out 37 pts who completed the therapy demonstrating CR. The 2-year PFS was 87% (95% CI 71–94), 2-year OS was 92% (95% CI 78–97). In PEL, BV-monotherapy resulted in long lasting CR in 2/4 pts (>39 and >17 month, respectively). All 4 pts were alive at 12 months. CPI treatment resulted in CR in 1/7 PEL pts (PR: 2/7, SD: 2/7) and all 7 were alive at 6 months. More detailed data and an analysis comparing treatment outcomes in PLWH with those without HIV will be presented at the conference.

Conclusions Novel immunotherapeutic and targeted therapies appear safe and effective in PLWH. CAR-T-cells tend to show somewhat inferior outcomes in DLBCL, whereas BV-combinations and CPI treatment appear to result in favorable outcomes in cHL, compared to HIV-negative lymphoma. However, since data remains limited, it is essential to include PLWH in clinical trials.

Nathalie Lehnen: Abbvie - Honoraria